Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label …
ET Overton, G Richmond, G Rizzardini, H Jaeger… - The Lancet, 2020 - thelancet.com
Background Phase 3 clinical studies showed non-inferiority of long-acting intramuscular
cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important …
cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important …
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label …
H Jaeger, ET Overton, G Richmond, G Rizzardini… - The Lancet …, 2021 - thelancet.com
Background Long-acting cabotegravir and rilpivirine administered monthly or every 2
months might address the challenges associated with daily oral antiretroviral therapy. The …
months might address the challenges associated with daily oral antiretroviral therapy. The …
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority …
DA Margolis, J Gonzalez-Garcia, HJ Stellbrink, JJ Eron… - The Lancet, 2017 - thelancet.com
Background Cabotegravir and rilpivirine are antiretroviral drugs in development as long-
acting injectable formulations. The LATTE-2 study evaluated long-acting cabotegravir plus …
acting injectable formulations. The LATTE-2 study evaluated long-acting cabotegravir plus …
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Background There is a need for more convenient, less frequent treatment to help address
challenges associated with daily oral HIV treatment in people living with HIV, including …
challenges associated with daily oral HIV treatment in people living with HIV, including …
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a …
ET Overton, G Richmond, G Rizzardini… - Clinical Infectious …, 2023 - academic.oup.com
Abstract Background Cabotegravir (CAB)+ rilpivirine (RPV) dosed intramuscularly monthly
or every 2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 …
or every 2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 …
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase …
Background Previous work established non-inferiority of switching participants who were
virologically suppressed from daily oral standard of care to monthly long-acting …
virologically suppressed from daily oral standard of care to monthly long-acting …
[HTML][HTML] Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
S Swindells, T Lutz, L Van Zyl, N Porteiro, M Stoll… - Aids, 2022 - journals.lww.com
Background: ATLAS (NCT02951052), a phase 3, multicenter, open-label study,
demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long …
demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long …
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 …
DA Margolis, CC Brinson, GHR Smith… - The Lancet infectious …, 2015 - thelancet.com
Background In phase 1 trials, the HIV-1 integrase strand transfer inhibitor cabotegravir
(GSK1265744) was well tolerated, both alone, and in combination with the non-nucleoside …
(GSK1265744) was well tolerated, both alone, and in combination with the non-nucleoside …
Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
C Fernandez, CL van Halsema - HIV/AIDS-Research and Palliative …, 2019 - Taylor & Francis
Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of
HIV-1 infection brings promise of a new mode of delivery and potential solutions to some …
HIV-1 infection brings promise of a new mode of delivery and potential solutions to some …
[HTML][HTML] Long-acting injectable cabotegravir+ rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials
G Rizzardini, ET Overton, C Orkin… - JAIDS Journal of …, 2020 - journals.lww.com
Background: Long-acting (LA) injectable regimens are a potential therapeutic option in
people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were …
people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were …